Researchers at ISB have developed personalized models to predict C. diff colonization risk and test targeted probiotics. This approach could prevent infection before it starts and paves the way for precision microbiome therapies tailored to individual gut ecosystems.
ISB scientists have developed a simple, low-cost method to measure the total amount of bacteria in the gut using existing sequencing data. This breakthrough could speed up microbiome research and unlock new insights into health and disease.
The Biomedical Data Translator is now publicly available, offering a powerful open-source platform that integrates diverse biomedical datasets. Designed to accelerate discovery and patient care, Translator helps users explore complex data and uncover actionable insights with ease.
Institute for Systems Biology (ISB) is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including aging, brain health, cancer, COVID-19, as well as many infectious diseases. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence, one of the largest not-for-profit health care systems in the United States.